Barclays Initiates Coverage On Cellectis with Overweight Rating, Announces Price Target of $9
Benzinga Newsdesk 5 months ago
NewsPrice TargetInitiationAnalyst Ratings
Barclays analyst Lukas Shumway initiates coverage on Cellectis (NASDAQ:CLLS) with a Overweight rating and announces Price Target of $9.
Barclays analyst Lukas Shumway initiates coverage on Cellectis (NASDAQ:CLLS) with a Overweight rating and announces Price Target of $9.